CA1338344C - Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulations - Google Patents
Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulationsInfo
- Publication number
- CA1338344C CA1338344C CA000583952A CA583952A CA1338344C CA 1338344 C CA1338344 C CA 1338344C CA 000583952 A CA000583952 A CA 000583952A CA 583952 A CA583952 A CA 583952A CA 1338344 C CA1338344 C CA 1338344C
- Authority
- CA
- Canada
- Prior art keywords
- compound
- ramipril
- protective coating
- formula
- weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G59/00—Polycondensates containing more than one epoxy group per molecule; Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups
- C08G59/18—Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups ; e.g. general methods of curing
- C08G59/40—Macromolecules obtained by polymerising compounds containing more than one epoxy group per molecule using curing agents or catalysts which react with the epoxy groups ; e.g. general methods of curing characterised by the curing agents used
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Abstract
Stabilized compounds of the formula I
I
in which R, R1, R2, R3, R4 and R5 have the stated meanings, and a process for the preparation thereof, are described. The stabilized compounds are suitable for the manufacture of medicinal formulations.
I
in which R, R1, R2, R3, R4 and R5 have the stated meanings, and a process for the preparation thereof, are described. The stabilized compounds are suitable for the manufacture of medicinal formulations.
Description
Description: 13~834~
Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulations Compounds of the formula I
o C ~R
0 RS-N~ ~C~
* COOR2 R4--C~ ~--CH--CH2--CH2--R
C H
\ OR 3 in ~hich R is hydrogen, C1-C4-alkyl or phenyl, 1 ~ A
R represents C1-C4-alkyl or (CH2)m-N , in ~hich m is 1, 2, 3 or 4, and A and B are identical or different and denote hydrogen or C1-C4-alkyl, R2 is hydrogen, C1-C4-alkyl or benzyl, R3 is hydrogen or C1-C4-alkyl, and R4 and R5 denote, together ~ith the atoms carrying them, a heterocyclic, mono-, bi- or tricyclic hydrogenated or partially hydrogenated ring system ~hich has one nitrogen atom and 4 to 15 ring carbon atoms and ~hich is optionally mono- or disubstituted by C1-C4-alkoxy, represent valuable pharmaceuticals. They are, for ex-ample, inhibitors of angiotensin converting enzyme (ACE) and can be used to control high blood pressure of various etiologies. A nootropic action of these compounds has also been described (cf. German Offen-legungsschrift 3,610,391, corresponding to EP-A
0,243,645. The compounds of the formula I are disclosed in, for example, EP-A 79,022 and EP-A 50,800; in addition, reference may also be made to the citations quoted in German Offenlegungsschrift 3,610,391.
~" ~
Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulations Compounds of the formula I
o C ~R
0 RS-N~ ~C~
* COOR2 R4--C~ ~--CH--CH2--CH2--R
C H
\ OR 3 in ~hich R is hydrogen, C1-C4-alkyl or phenyl, 1 ~ A
R represents C1-C4-alkyl or (CH2)m-N , in ~hich m is 1, 2, 3 or 4, and A and B are identical or different and denote hydrogen or C1-C4-alkyl, R2 is hydrogen, C1-C4-alkyl or benzyl, R3 is hydrogen or C1-C4-alkyl, and R4 and R5 denote, together ~ith the atoms carrying them, a heterocyclic, mono-, bi- or tricyclic hydrogenated or partially hydrogenated ring system ~hich has one nitrogen atom and 4 to 15 ring carbon atoms and ~hich is optionally mono- or disubstituted by C1-C4-alkoxy, represent valuable pharmaceuticals. They are, for ex-ample, inhibitors of angiotensin converting enzyme (ACE) and can be used to control high blood pressure of various etiologies. A nootropic action of these compounds has also been described (cf. German Offen-legungsschrift 3,610,391, corresponding to EP-A
0,243,645. The compounds of the formula I are disclosed in, for example, EP-A 79,022 and EP-A 50,800; in addition, reference may also be made to the citations quoted in German Offenlegungsschrift 3,610,391.
~" ~
- 2 - 133834~
The active substances of the formula I are preferabLy administered orally, and solid administration forms such as, for example, tablets, coated tablets or capsules are particularly suitable.
It has been found that active substances of the formula I, such as, for example, 2-tN-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl~-(1S,3S,5S)-2-azabicyclo[3.3.0]-octane-3-carboxylic acid (ramipril), show a tendency to be unstable in pharmaceutical formulations, depending on the auxiliaries used, the manufacturing process and the storage.
The main product of decomposition which has been - 15 detected in pharmaceutical formulations is the diketo-- piperazine compound produced by condensation and having the following structure II
RS- N ~ ~
R'l- CH ~--CH-CH2--CHZ--R II
--C ~ COOR2 o Accordingly, the main product of decomposition of rami-pril is the diketopiperazine derivative of the formula IIa C~2 - CUz - ~CI~
(5) It has been found that the stability can be influenced by the choice of suitable auxiliaries, and that a sig-nificant cause of decomposition is the mechanical stress associated with the manufacturing process, especially when the active substance, for example ramipril, is present in a mixture with auxiliaries.
The investigation which is summarized in the table beLow illustrates the decomposition-inducing effect of the mechanical stress, taking ramipril as example.
2.5 mg ramipril tablets/effect of mechanical stress on stability.
Diketopiperazine derivative of ramipriL (X) Duration and 2.5 mg 2.5 mg 2.5 mg nature of stress tablets tablets capsules ~ 3 mon. + 40C 13.6 7.6 4.0 6 mon. + 40C 22.8 12.û 6.4 manufacturing dry direct filling 20 process granulation compres- with the sion powdered mixture mechanical stress high moderate low The three formulations compared have the same compos-ition and contain the following auxiliaries: mannitol, microcrystalline cellulose, and sodium stearylfumarate.
The only difference is in the power of compression (mechan.
stress) involved in the process.
The results clearly show that the mechanical stress is a significant decomposition-inducing factor.
It has also been found that the storage conditions in-fluence the stability of the active substances of the formula I.
- ~ ~ 4 ~ 13383~
Decomposition is favored by increasing temperature and moisture and by the two effects of storage acting to-gether.
The tendency of, for example, ramipril to decompose in formulations in which all the said influencing factors act together is revealed in the following comparative test:
Determinations were carried out of the contents of active substance after stress for a) the active substance itself; uncompressed b) ramipril tablets which contained several auxiliaries and had been exposed to mechanical stress (compres-slon):
~ 15 Duration and nature Content relative to initial value of stress Ramipril Ramipril active tablets substance 6 months + 40C 99% 56%
6 months + 40C 96% < 20%
80% rel. hum.
TabLets and auxiliaries used Lactose monohydrate, corn starch, microcrystalline cel-lulose, sodium starch glycolate, highly disperse silica, talc and magnesium stearate.
The results clearly show that, under the chosen test conditions, the stability of the uncompressed active substance is good. Only on compression (mechan. stress) with generally used tabletting auxiliaries and after exposure to heat and, especially, moisture is there a large decrease in the content of active substance.
- ~ - 5 - 13383~1 The preferred presentation for the active substances of the formula I is the tablet, because of the possibility of individual adjustment of the dose and better patient compliance. The presentations are, as shown by the above results, extremely unstable, especially when 1. mechanical stress (power of compression) 2. tabletting auxiliaries 3. temperature 4. moisture act together.
~hereas mechanical stresses are unavoidable in the manu-facture of formulations in compressed form, attempts have been made to obtain stable formulations by changing the - auxiliaries. Taking ramipril as example, it has been made possible to optimize the formula by choosing auxiliaries specifically for their compatibility with ramipril.
This is illustrated by the following comparison after exposure to stress.
Duration and nature 1 mg ramipril tablets 20 of stress Content relative to initial value Formula 1 Formula 2 (optimized formula) 6 months 40C 56% 88.5%
25 Auxiliaries lactose monohydrate, mannitol, maize starch, micro- micro-crystalline cellulose, crystalline Na starch glycolate, cellulose, highly disperse silica, Na stearyl-talc, fumarate magnesium stearate 13~8344 _ 6 However, this measure is not by itself sufficient to sta-bilize the tablet formulation. It has now been found, surprisingly, that a protective coating of the pure ramipril, which is prone to decompose, with polymeric film-formers counteracts the mechanical inactivation.
These findings were surprising because even small amounts of coating sufficed to shield the active substance from mechanical stress.
It has additionally been found that stable tablets suit-able for oral administration are obtained when the active substance of the formula I is mixed with a buffer which ensures that the pH which is set up in the formulation under the action of atmospheric humidity is in the weakly acid to weakly alkaline range (5.5 to 8.0).
Hence the invention relates to a method for the stabi-lization of active substances of the formula I, which comprises coating the active substance, or a mixture containing the active substance, with a polymeric pro-tective film, or comprises mixing the active substance of the formula I with a physiologically tolerated buffer which ensures that a pH in the weakly acid to weakly alkaline range is set up in a formulation in the presence of moisture, and active substances of the formula I which have been stabilized by a polymeric protective film or by mixture with a buffer. The active substances of the formula I can be present as such or as physiologically tolerated salts.
The centers of chirality at the carbon atoms in formula I marked with an asterisk (*) preferably have the S con-figuration.
Active substances of the formula I in which R, R1, R2and R3 have the following meanings:
R : methyl or phenyl, R : methyl or (CH2)4-NH2 R : hydrogen or ethyl, R3 : hydrogen, and in which R4 and R5 form, ~ith the atoms carrying them, preferably the following ring systems C-OR3 ~ C-oR3 O O
[~ ~ C- oR 3 ~ C- oR3 ~ C - OR 3 O O O
~here R3 is preferably hydrogen, are preferred.
Particularly suitable active substances are:
ramipril of the formula Ia C O O H
~ \ C - C~ H - CH - CHz ~ CHz ~ I a enalapril of the formula Ib CO2H /CHzCH2 ~ I b_ C -- CH -- NH - CH
perindopril of the formula Ic C02H / C~zCHzCH3 I c C -- CH - NH -- CH
C02Cz~5 indolapri~ of the for-ula Id 1338344 C02H CHzCHz- ~ I d ~ C - CH - NH - CH/
lisinopril of the formula Ie COzH CHzcHz- ~ I e C - CH - NH - CH/
( CHz)"~NHZ C02H
quinapril of the formula If (X= H) ~ alacepril of the formula If ~X= 3,4-OCH3) X ~ C2H
\ CHzCH2 ~ I f C ~ CH - NH ~ CH
trandolapril of the formula Ig H
COOH
C - CH - NH - CH - CH2 - CH2 ~ ~ I g CH3 Cooc2Hs and CGS 13928 C of the formula Ih l ~ CO2H CHzcHz ~ I h C - CH - NH - CH
0/ ~ ~
~ 9 ~ 133834~
Protective coatings in concentrations of as little as 3 to 25%, preferably 5 to 15% (per cent by weight relative to the active substance which is to be coated), are effective. It was not to be expected that even thin film S coatings are able to shield the contents from the high mechanical stresses customary in the tabletting process (5 KN to 30 KN).
It was additionally surprising that the polymers provided for the protective coating can be used as aqueous solu-tions without having an adverse effect on the stability.
Exa-pLes of poLy-ers suitabLe for the protective coating Cellulose derivatives such as, for example, hydroxy-propylcellulose, hydroxypropylmethylcellulose, hydroxy-~ propylmethylcellulose phthalate, hydroxyethylcellulose, ethylcellulose, cellulose acetate phthalate, celluloseacetate, polyvinyl acetate phthalate, polyvinylpyrroli-done, cationic and anionic polymers, copolymer with neutral character based on poly(meth)acrylic esters (Eudragit~ E, Eudragit~ E 30 D), anionic polymer of methacrylic acid and methyl methacrylate (Eudragit~ L
or S, Eudragit~ L 30 D) and gelatin. In principle, all physiologically tolerated polymers are suitable.
The protective coating can be carried out by dispersing the active substance with the solution or dispersion of the film-former in a suitable kneader, mixer or mixer-granulator. The uniformly wetted composition is then forced through a screen and dried. The dried granules are once more passed through a screen and then used to manufacture capsules or tablets. A particularly uniform coating is obtained in a fluidized bed. The particles of active substance are sprayed in the stream of air with a solution or dispersion of the polymer and are dried. The coated granules of active substance can be used immedi-ately after the drying process for filling capsules or for manufacturing tablets. 133834~
However, it is also possible to combine the two processes together by initially wetting the active substance with the solution or dispersion of the polymer in a kneader, mixer or mixer-granulator, and subsequently processing it by granulation to give homogeneous agglomerates which are then finally coated with the solution or dispersion of the polymer in a fluidized bed.
The active substances stabilized with a protective film by the method according to the invention can be processed to give capsules or compressed administration forms.
Such products are stable by comparison ~ith products which are manufactured with untreated active substance.
This is revealed best by the example of tablets in which ~ 15 the diminution in stability by the mechanical stress during manufacture becomes evident after subsequent exposure to heat.
A stability comparison with a standard formula without protective coating is shown in the table which follows.
- 11 - 13383~
Table 1 2.5 mg ramipril tablets StabiLity comparison/stabilizing effect of a protective coating Nature of stress: 6 months + 40C
Packaging: Glass tubes with tight screw closure Composition in mgStandard Tablets manufactured formula according to the invention as in Example 5 uncoated pure ramipril 2.50 87Z* pure ramipril - 2.87 * contains 13% HPMC
as film coating ~ 15 microcrystalline cellulose 47.00 47.00 free-flowing mannitol 49.50 49.13 Na stearylfumarate1.00 1.00 tablet weight 100.00 100.00 20 compressive force 10,000 N 10,000 N
decomposition to the diketopiperazine breakdown product in Z 12.72 1.87 Table 2 which follows demonstrates that a relatively thin coating of ramipril is still effective even after lengthy stress.
Table 2 133834~
2.5 mg ramipriL tablets Stability comparison Nature of stress: 12 months + 40C
Packaging: Glass tubes with tight screw closure Composition in mg Standard Tablets manufactured formula according to the invention as in Example 6 uncoated pure ramipril 2.50 94%* pure ramipril - 2.66 * contains 6% HPMC
as film coating - microcrystalline 15 cellulose 25.00 25.00 free-flowing mannitol 71.50 71.34 Na stearylfumarate1.00 1.00 tablet weight 100.00 100.00 compressive force 20 during tabletting10,000 N10,000 N
decomposition to the diketopiperazine breakdown product in % 25.34 5.97 On stabilization by admixture of a buffer, the latter is mixed either with the active substance or with the coated active substance, during which the active substance or the coated active substance is being granulated with a buffer solution or is present in the dispersion or solu-tion of the polymeric substance when both types of stabilization are used simultaneously.
The pH set up in the formulation, such as, for example, ~_ - 13 - 133834~
a tablet, in the presence of moisture, such as, for example, atmospheric humidity or water, is bet~een 5.5 and 8Ø
Examples of suitable buffer substances are: sodium di-hydrogen phosphate dihydrate, trisodium citrate dihydrate, sodium carbonate, sodium hydrogen carbonate and tris-(hydroxymethyl)aminomethane.
It is advantageous if the buffer substance is used as an aqueous solution, by the active substance being either moistened uniformly in a suitable mixer, kneader or mixer-granulator and then granulated and dried, or sprayed in a fluidized bed and spray-granulated in this way. Ho~ever, it is also possible to granulate a mixture of active substance and buffer substance ~ith ~ater in - 15 the manner described.
It has proved particularly advantageous if the stabiliz-ing effect produced by mixture ~ith buffer is combined ~ith a protective coating of the particles of active substance by polymeric film-formers.
This is carried out most advantageously in such a ~ay that the buffer substance is already dissolved in the medium intended for coating the particles and is appli-ed together with the polymeric film-former to the surface of the active substance. The coating techniques des-cribed for coating the particles are used for this.
The stabilizing effect of buffer substances is illustra-ted by the comparison in the follo~ing table (Table 3).
Table 3 133834~
2.5 mg ramipril tablets Stability comparison/stabilizing effect of buffer substances Nature of stress: 3 months + 40C
Packaging: Glass tubes ~ith tight screw closure Composition in mg Standard Tablets manufactured formula according to the invention as in 1Q Example 7 pure ramipril 2.5 2.5 tris(hydroxymethyl)-aminomethane - 2.5 ~ pregelatinized 15 starch 51.5 49.0 microcrystalline cellulose 45.0 45.0 Na stearylfumarate 1.0 1.0 tablet weight 100.0 100.0 compressive force during tabletting10,000 N10,000 N
pH after suspending in water 5.4 6.9 decomposition to diketopiperazine breakdown product in % 7.1 0.6 _ - 15 -Use Exa-pLes 13 3 8 3 ~ ~
ExampLe 1 Preparation of stabiLized pure ramipriL
87 parts by weight of pure ramipril are granulated in a fluidized bed apparatus with 13 parts by weight of hydroxypropylmethylcellulose, called HPMC hereinafter, as a 5% strength aqueous solution. Examples of suitable types are Pharmacoa ~ 606 or Methocel~ E5 Premium.
The process takes place in two sections, in which the pure ramipril is first granulated with one half of the HPMC solution and then coated with the second half of the 5% strength aqueous HPMC solution.
The drying temperature is about 50C. The coated pure - ramipril can be mixed with auxiliaries and used to fill capsules or compressed directly, without other granula-tion steps, to tablets.
ExampLe 2 Preparation of stabiLized pure ra-ipriL
94 parts by weight of pure ramipril are dispersed in a suitable kneader, mixer or mixer-granulator with 6 parts by weight of HPMC as a 10% strength aqueous solution until a uniformly moistened composition results. The moist composition is passed through a screen with a mesh size of 1.2 mm and is then dried at about 40C. The dried agglomerates are once more passed through a screen with a mesh size of 0.5 to 1 mm. The finished ramipril granules can be used to manufacture capsules or tablets.
Example 3 Preparation of stabiLized pure ra-ipriL
1 part by weight of pure ramipril and 1 part by weight of tris(hydroxymethyl)aminomethane buffer substance are mixed in a suitable mixer or mixer-granuLator and then moistened with sufficient purified water to produce a uniformLy wetted composition.
The moist composition is granulated in the manner des-cribed in Example 2.
ExampLe 4 Preparation of stabiLized pure ramipriL
94 parts by ~eight of pure ramipril, 6 parts by weight of polyvinylpyrrolidone (for example Kollido ~ K25) and 18.8 parts by weight of sodium carbonate are mixed in a suitable mixer or mixer-granulator and then moistened with sufficient purified water to produce a uniformly wetted composition. The moist composition is granulated in the manner described in Example Z.
ExampLe 5 ~anufacture of 10,000 2.5 9 ramipriL tabLets Z8.7 9 of 87% pure ramipril (contains 13% HPMC as film coating as in Example 1), 470 9 of microcrystalline cellulose and 491.3 g of free-flowing mannitol are mixed.
In a second step, 10 9 of sodium stearylfumarate are mixed into this mixture. 1-kg of the mixture prepared in this way is compressed directly, without other granu-lation steps, to tablets having a final weight of 100 mg.
ExampLe 6 ~anufacture of 10,000 2.5 9 ramipriL tabLets 26.6 9 of 94% pure ramipril (contains 6% HPMC as film coating as in Example 2), 250 g of microcrystalline cellulose and 713.4 9 of free-flowing mannitol are mixed.
In a second step, 10 9 of sodium stearylfumarate are mixed into this mixture.
1 kg of the mixture prepared in this way is compressed directly, without other granulation steps, to tablets having a finaL weight of 100 mg.
Exa-ple 7 ~anufacture of 10,000 2.5 mg ramipril tablets 50 9 of 50% pure ramipril, prepared as in Example 3, 450 9 of microcrystalline cellulose and 490 9 of pre-gelatinized starch are mixed. In a second step, 10 9 of sodium stearylfumarate are mixed into this mixture.
1 kg of the mixture prepared in this way is compressed directly, without other granulation steps, to tablets having a final weight of 100 mg.
- Exa-ple 8 ~anufacture of 10,000 5 9 ramipril tablets 63 9 of ramipril stabilized as in Example 4, 250 9 of microcrystalline cellulose and 667 9 of free-flowing mannitol are mixed In a second step, 20 9 of sodium stearylfumarate are mixed into this mixture.
1 kg of this mixture are compressed directly, without other granulation steps, to tablets having a final weight of 100 mg.
Exa-ple 9 Preparation of stabi~ized pure enalapril 85 parts by ~eight of enalapril hydrogen maleate are granulated in a fluidized bed apparatus with 15 parts by weight of hydroxypropylmethylcellulose (HPMC) as a 5%
strength aqueous solution in the manner indicated in Example 1. The coated pure enalapril can be mixed with auxiliaries and used to fill capsules or compressed directly, without other granulation steps, to tablets.
Example 10 Preparation of stabilized pure enalapril 90 parts by weight of enalapril hydrogen maleate are dispersed in a suitable kneader, mixer or mixer-granula-tor with 10 parts by weight of HPMC as an aqueous solu-tion until a uniformly moistened composition is produced.
The moist enalapril composition is granulated in the manner described in Example 2. The finished enalapril granules with a protective coating can be used to manu-facture capsules or tablets.
Exa-ple 11 Manufacture of 10,000 2.5 ng enalapril tablets 29.4 9 of 85% pure enalapril hydrogen maleate (contains ~ 15% HPMC as film coating as in Example 9), 480 9 of microcrystalline cellulose and 480.6 9 of modified free-flowing starch are mixed. In a second step, 10 9 of sodium stearylfumarate are mixed into this mixture. 1 kg of this mixture is compressed directly, without other granulation steps, to tablets having a final weight of 100 mg.
Exa-ple 12 Manufacture of 10,000 10 9 enalapril tablets 111.1 9 of 90% pure enalapril hydrogen maleate (contains 10% HPMC as film coating as in Example 10), 480 9 of microcrystalline cellulose and 398.9 9 of modified free-flowing starch are mixed. In a second step, 10 9 of sodium stearylfumarate are mixed into this mixture. 1 kg of this mixture is compressed directly, without other granulation steps, to tablets having a final weight of 100 mg.
The active substances of the formula I are preferabLy administered orally, and solid administration forms such as, for example, tablets, coated tablets or capsules are particularly suitable.
It has been found that active substances of the formula I, such as, for example, 2-tN-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl~-(1S,3S,5S)-2-azabicyclo[3.3.0]-octane-3-carboxylic acid (ramipril), show a tendency to be unstable in pharmaceutical formulations, depending on the auxiliaries used, the manufacturing process and the storage.
The main product of decomposition which has been - 15 detected in pharmaceutical formulations is the diketo-- piperazine compound produced by condensation and having the following structure II
RS- N ~ ~
R'l- CH ~--CH-CH2--CHZ--R II
--C ~ COOR2 o Accordingly, the main product of decomposition of rami-pril is the diketopiperazine derivative of the formula IIa C~2 - CUz - ~CI~
(5) It has been found that the stability can be influenced by the choice of suitable auxiliaries, and that a sig-nificant cause of decomposition is the mechanical stress associated with the manufacturing process, especially when the active substance, for example ramipril, is present in a mixture with auxiliaries.
The investigation which is summarized in the table beLow illustrates the decomposition-inducing effect of the mechanical stress, taking ramipril as example.
2.5 mg ramipril tablets/effect of mechanical stress on stability.
Diketopiperazine derivative of ramipriL (X) Duration and 2.5 mg 2.5 mg 2.5 mg nature of stress tablets tablets capsules ~ 3 mon. + 40C 13.6 7.6 4.0 6 mon. + 40C 22.8 12.û 6.4 manufacturing dry direct filling 20 process granulation compres- with the sion powdered mixture mechanical stress high moderate low The three formulations compared have the same compos-ition and contain the following auxiliaries: mannitol, microcrystalline cellulose, and sodium stearylfumarate.
The only difference is in the power of compression (mechan.
stress) involved in the process.
The results clearly show that the mechanical stress is a significant decomposition-inducing factor.
It has also been found that the storage conditions in-fluence the stability of the active substances of the formula I.
- ~ ~ 4 ~ 13383~
Decomposition is favored by increasing temperature and moisture and by the two effects of storage acting to-gether.
The tendency of, for example, ramipril to decompose in formulations in which all the said influencing factors act together is revealed in the following comparative test:
Determinations were carried out of the contents of active substance after stress for a) the active substance itself; uncompressed b) ramipril tablets which contained several auxiliaries and had been exposed to mechanical stress (compres-slon):
~ 15 Duration and nature Content relative to initial value of stress Ramipril Ramipril active tablets substance 6 months + 40C 99% 56%
6 months + 40C 96% < 20%
80% rel. hum.
TabLets and auxiliaries used Lactose monohydrate, corn starch, microcrystalline cel-lulose, sodium starch glycolate, highly disperse silica, talc and magnesium stearate.
The results clearly show that, under the chosen test conditions, the stability of the uncompressed active substance is good. Only on compression (mechan. stress) with generally used tabletting auxiliaries and after exposure to heat and, especially, moisture is there a large decrease in the content of active substance.
- ~ - 5 - 13383~1 The preferred presentation for the active substances of the formula I is the tablet, because of the possibility of individual adjustment of the dose and better patient compliance. The presentations are, as shown by the above results, extremely unstable, especially when 1. mechanical stress (power of compression) 2. tabletting auxiliaries 3. temperature 4. moisture act together.
~hereas mechanical stresses are unavoidable in the manu-facture of formulations in compressed form, attempts have been made to obtain stable formulations by changing the - auxiliaries. Taking ramipril as example, it has been made possible to optimize the formula by choosing auxiliaries specifically for their compatibility with ramipril.
This is illustrated by the following comparison after exposure to stress.
Duration and nature 1 mg ramipril tablets 20 of stress Content relative to initial value Formula 1 Formula 2 (optimized formula) 6 months 40C 56% 88.5%
25 Auxiliaries lactose monohydrate, mannitol, maize starch, micro- micro-crystalline cellulose, crystalline Na starch glycolate, cellulose, highly disperse silica, Na stearyl-talc, fumarate magnesium stearate 13~8344 _ 6 However, this measure is not by itself sufficient to sta-bilize the tablet formulation. It has now been found, surprisingly, that a protective coating of the pure ramipril, which is prone to decompose, with polymeric film-formers counteracts the mechanical inactivation.
These findings were surprising because even small amounts of coating sufficed to shield the active substance from mechanical stress.
It has additionally been found that stable tablets suit-able for oral administration are obtained when the active substance of the formula I is mixed with a buffer which ensures that the pH which is set up in the formulation under the action of atmospheric humidity is in the weakly acid to weakly alkaline range (5.5 to 8.0).
Hence the invention relates to a method for the stabi-lization of active substances of the formula I, which comprises coating the active substance, or a mixture containing the active substance, with a polymeric pro-tective film, or comprises mixing the active substance of the formula I with a physiologically tolerated buffer which ensures that a pH in the weakly acid to weakly alkaline range is set up in a formulation in the presence of moisture, and active substances of the formula I which have been stabilized by a polymeric protective film or by mixture with a buffer. The active substances of the formula I can be present as such or as physiologically tolerated salts.
The centers of chirality at the carbon atoms in formula I marked with an asterisk (*) preferably have the S con-figuration.
Active substances of the formula I in which R, R1, R2and R3 have the following meanings:
R : methyl or phenyl, R : methyl or (CH2)4-NH2 R : hydrogen or ethyl, R3 : hydrogen, and in which R4 and R5 form, ~ith the atoms carrying them, preferably the following ring systems C-OR3 ~ C-oR3 O O
[~ ~ C- oR 3 ~ C- oR3 ~ C - OR 3 O O O
~here R3 is preferably hydrogen, are preferred.
Particularly suitable active substances are:
ramipril of the formula Ia C O O H
~ \ C - C~ H - CH - CHz ~ CHz ~ I a enalapril of the formula Ib CO2H /CHzCH2 ~ I b_ C -- CH -- NH - CH
perindopril of the formula Ic C02H / C~zCHzCH3 I c C -- CH - NH -- CH
C02Cz~5 indolapri~ of the for-ula Id 1338344 C02H CHzCHz- ~ I d ~ C - CH - NH - CH/
lisinopril of the formula Ie COzH CHzcHz- ~ I e C - CH - NH - CH/
( CHz)"~NHZ C02H
quinapril of the formula If (X= H) ~ alacepril of the formula If ~X= 3,4-OCH3) X ~ C2H
\ CHzCH2 ~ I f C ~ CH - NH ~ CH
trandolapril of the formula Ig H
COOH
C - CH - NH - CH - CH2 - CH2 ~ ~ I g CH3 Cooc2Hs and CGS 13928 C of the formula Ih l ~ CO2H CHzcHz ~ I h C - CH - NH - CH
0/ ~ ~
~ 9 ~ 133834~
Protective coatings in concentrations of as little as 3 to 25%, preferably 5 to 15% (per cent by weight relative to the active substance which is to be coated), are effective. It was not to be expected that even thin film S coatings are able to shield the contents from the high mechanical stresses customary in the tabletting process (5 KN to 30 KN).
It was additionally surprising that the polymers provided for the protective coating can be used as aqueous solu-tions without having an adverse effect on the stability.
Exa-pLes of poLy-ers suitabLe for the protective coating Cellulose derivatives such as, for example, hydroxy-propylcellulose, hydroxypropylmethylcellulose, hydroxy-~ propylmethylcellulose phthalate, hydroxyethylcellulose, ethylcellulose, cellulose acetate phthalate, celluloseacetate, polyvinyl acetate phthalate, polyvinylpyrroli-done, cationic and anionic polymers, copolymer with neutral character based on poly(meth)acrylic esters (Eudragit~ E, Eudragit~ E 30 D), anionic polymer of methacrylic acid and methyl methacrylate (Eudragit~ L
or S, Eudragit~ L 30 D) and gelatin. In principle, all physiologically tolerated polymers are suitable.
The protective coating can be carried out by dispersing the active substance with the solution or dispersion of the film-former in a suitable kneader, mixer or mixer-granulator. The uniformly wetted composition is then forced through a screen and dried. The dried granules are once more passed through a screen and then used to manufacture capsules or tablets. A particularly uniform coating is obtained in a fluidized bed. The particles of active substance are sprayed in the stream of air with a solution or dispersion of the polymer and are dried. The coated granules of active substance can be used immedi-ately after the drying process for filling capsules or for manufacturing tablets. 133834~
However, it is also possible to combine the two processes together by initially wetting the active substance with the solution or dispersion of the polymer in a kneader, mixer or mixer-granulator, and subsequently processing it by granulation to give homogeneous agglomerates which are then finally coated with the solution or dispersion of the polymer in a fluidized bed.
The active substances stabilized with a protective film by the method according to the invention can be processed to give capsules or compressed administration forms.
Such products are stable by comparison ~ith products which are manufactured with untreated active substance.
This is revealed best by the example of tablets in which ~ 15 the diminution in stability by the mechanical stress during manufacture becomes evident after subsequent exposure to heat.
A stability comparison with a standard formula without protective coating is shown in the table which follows.
- 11 - 13383~
Table 1 2.5 mg ramipril tablets StabiLity comparison/stabilizing effect of a protective coating Nature of stress: 6 months + 40C
Packaging: Glass tubes with tight screw closure Composition in mgStandard Tablets manufactured formula according to the invention as in Example 5 uncoated pure ramipril 2.50 87Z* pure ramipril - 2.87 * contains 13% HPMC
as film coating ~ 15 microcrystalline cellulose 47.00 47.00 free-flowing mannitol 49.50 49.13 Na stearylfumarate1.00 1.00 tablet weight 100.00 100.00 20 compressive force 10,000 N 10,000 N
decomposition to the diketopiperazine breakdown product in Z 12.72 1.87 Table 2 which follows demonstrates that a relatively thin coating of ramipril is still effective even after lengthy stress.
Table 2 133834~
2.5 mg ramipriL tablets Stability comparison Nature of stress: 12 months + 40C
Packaging: Glass tubes with tight screw closure Composition in mg Standard Tablets manufactured formula according to the invention as in Example 6 uncoated pure ramipril 2.50 94%* pure ramipril - 2.66 * contains 6% HPMC
as film coating - microcrystalline 15 cellulose 25.00 25.00 free-flowing mannitol 71.50 71.34 Na stearylfumarate1.00 1.00 tablet weight 100.00 100.00 compressive force 20 during tabletting10,000 N10,000 N
decomposition to the diketopiperazine breakdown product in % 25.34 5.97 On stabilization by admixture of a buffer, the latter is mixed either with the active substance or with the coated active substance, during which the active substance or the coated active substance is being granulated with a buffer solution or is present in the dispersion or solu-tion of the polymeric substance when both types of stabilization are used simultaneously.
The pH set up in the formulation, such as, for example, ~_ - 13 - 133834~
a tablet, in the presence of moisture, such as, for example, atmospheric humidity or water, is bet~een 5.5 and 8Ø
Examples of suitable buffer substances are: sodium di-hydrogen phosphate dihydrate, trisodium citrate dihydrate, sodium carbonate, sodium hydrogen carbonate and tris-(hydroxymethyl)aminomethane.
It is advantageous if the buffer substance is used as an aqueous solution, by the active substance being either moistened uniformly in a suitable mixer, kneader or mixer-granulator and then granulated and dried, or sprayed in a fluidized bed and spray-granulated in this way. Ho~ever, it is also possible to granulate a mixture of active substance and buffer substance ~ith ~ater in - 15 the manner described.
It has proved particularly advantageous if the stabiliz-ing effect produced by mixture ~ith buffer is combined ~ith a protective coating of the particles of active substance by polymeric film-formers.
This is carried out most advantageously in such a ~ay that the buffer substance is already dissolved in the medium intended for coating the particles and is appli-ed together with the polymeric film-former to the surface of the active substance. The coating techniques des-cribed for coating the particles are used for this.
The stabilizing effect of buffer substances is illustra-ted by the comparison in the follo~ing table (Table 3).
Table 3 133834~
2.5 mg ramipril tablets Stability comparison/stabilizing effect of buffer substances Nature of stress: 3 months + 40C
Packaging: Glass tubes ~ith tight screw closure Composition in mg Standard Tablets manufactured formula according to the invention as in 1Q Example 7 pure ramipril 2.5 2.5 tris(hydroxymethyl)-aminomethane - 2.5 ~ pregelatinized 15 starch 51.5 49.0 microcrystalline cellulose 45.0 45.0 Na stearylfumarate 1.0 1.0 tablet weight 100.0 100.0 compressive force during tabletting10,000 N10,000 N
pH after suspending in water 5.4 6.9 decomposition to diketopiperazine breakdown product in % 7.1 0.6 _ - 15 -Use Exa-pLes 13 3 8 3 ~ ~
ExampLe 1 Preparation of stabiLized pure ramipriL
87 parts by weight of pure ramipril are granulated in a fluidized bed apparatus with 13 parts by weight of hydroxypropylmethylcellulose, called HPMC hereinafter, as a 5% strength aqueous solution. Examples of suitable types are Pharmacoa ~ 606 or Methocel~ E5 Premium.
The process takes place in two sections, in which the pure ramipril is first granulated with one half of the HPMC solution and then coated with the second half of the 5% strength aqueous HPMC solution.
The drying temperature is about 50C. The coated pure - ramipril can be mixed with auxiliaries and used to fill capsules or compressed directly, without other granula-tion steps, to tablets.
ExampLe 2 Preparation of stabiLized pure ra-ipriL
94 parts by weight of pure ramipril are dispersed in a suitable kneader, mixer or mixer-granulator with 6 parts by weight of HPMC as a 10% strength aqueous solution until a uniformly moistened composition results. The moist composition is passed through a screen with a mesh size of 1.2 mm and is then dried at about 40C. The dried agglomerates are once more passed through a screen with a mesh size of 0.5 to 1 mm. The finished ramipril granules can be used to manufacture capsules or tablets.
Example 3 Preparation of stabiLized pure ra-ipriL
1 part by weight of pure ramipril and 1 part by weight of tris(hydroxymethyl)aminomethane buffer substance are mixed in a suitable mixer or mixer-granuLator and then moistened with sufficient purified water to produce a uniformLy wetted composition.
The moist composition is granulated in the manner des-cribed in Example 2.
ExampLe 4 Preparation of stabiLized pure ramipriL
94 parts by ~eight of pure ramipril, 6 parts by weight of polyvinylpyrrolidone (for example Kollido ~ K25) and 18.8 parts by weight of sodium carbonate are mixed in a suitable mixer or mixer-granulator and then moistened with sufficient purified water to produce a uniformly wetted composition. The moist composition is granulated in the manner described in Example Z.
ExampLe 5 ~anufacture of 10,000 2.5 9 ramipriL tabLets Z8.7 9 of 87% pure ramipril (contains 13% HPMC as film coating as in Example 1), 470 9 of microcrystalline cellulose and 491.3 g of free-flowing mannitol are mixed.
In a second step, 10 9 of sodium stearylfumarate are mixed into this mixture. 1-kg of the mixture prepared in this way is compressed directly, without other granu-lation steps, to tablets having a final weight of 100 mg.
ExampLe 6 ~anufacture of 10,000 2.5 9 ramipriL tabLets 26.6 9 of 94% pure ramipril (contains 6% HPMC as film coating as in Example 2), 250 g of microcrystalline cellulose and 713.4 9 of free-flowing mannitol are mixed.
In a second step, 10 9 of sodium stearylfumarate are mixed into this mixture.
1 kg of the mixture prepared in this way is compressed directly, without other granulation steps, to tablets having a finaL weight of 100 mg.
Exa-ple 7 ~anufacture of 10,000 2.5 mg ramipril tablets 50 9 of 50% pure ramipril, prepared as in Example 3, 450 9 of microcrystalline cellulose and 490 9 of pre-gelatinized starch are mixed. In a second step, 10 9 of sodium stearylfumarate are mixed into this mixture.
1 kg of the mixture prepared in this way is compressed directly, without other granulation steps, to tablets having a final weight of 100 mg.
- Exa-ple 8 ~anufacture of 10,000 5 9 ramipril tablets 63 9 of ramipril stabilized as in Example 4, 250 9 of microcrystalline cellulose and 667 9 of free-flowing mannitol are mixed In a second step, 20 9 of sodium stearylfumarate are mixed into this mixture.
1 kg of this mixture are compressed directly, without other granulation steps, to tablets having a final weight of 100 mg.
Exa-ple 9 Preparation of stabi~ized pure enalapril 85 parts by ~eight of enalapril hydrogen maleate are granulated in a fluidized bed apparatus with 15 parts by weight of hydroxypropylmethylcellulose (HPMC) as a 5%
strength aqueous solution in the manner indicated in Example 1. The coated pure enalapril can be mixed with auxiliaries and used to fill capsules or compressed directly, without other granulation steps, to tablets.
Example 10 Preparation of stabilized pure enalapril 90 parts by weight of enalapril hydrogen maleate are dispersed in a suitable kneader, mixer or mixer-granula-tor with 10 parts by weight of HPMC as an aqueous solu-tion until a uniformly moistened composition is produced.
The moist enalapril composition is granulated in the manner described in Example 2. The finished enalapril granules with a protective coating can be used to manu-facture capsules or tablets.
Exa-ple 11 Manufacture of 10,000 2.5 ng enalapril tablets 29.4 9 of 85% pure enalapril hydrogen maleate (contains ~ 15% HPMC as film coating as in Example 9), 480 9 of microcrystalline cellulose and 480.6 9 of modified free-flowing starch are mixed. In a second step, 10 9 of sodium stearylfumarate are mixed into this mixture. 1 kg of this mixture is compressed directly, without other granulation steps, to tablets having a final weight of 100 mg.
Exa-ple 12 Manufacture of 10,000 10 9 enalapril tablets 111.1 9 of 90% pure enalapril hydrogen maleate (contains 10% HPMC as film coating as in Example 10), 480 9 of microcrystalline cellulose and 398.9 9 of modified free-flowing starch are mixed. In a second step, 10 9 of sodium stearylfumarate are mixed into this mixture. 1 kg of this mixture is compressed directly, without other granulation steps, to tablets having a final weight of 100 mg.
Claims (20)
1. A stable pharmaceutical composition in compressed form comprising a compound of the formula I
(I) in which R is hydrogen, C1-C4-alkyl or phenyl, R represents C1-C4-alkyl or , in which m is 1, 2, 3 or 4, and A and B are identical or different and denote hydrogen or C1-C4-alkyl, R2 is hydrogen, C1-C4-alkyl or benzyl, R3 is hydrogen or C1-C4-alkyl, and R4 and R5 denote, together with the atoms carrying them, a heterocyclic, mono-, bi- or tricyclic hydrogenated or partially hydrogenated ring system which has one nitrogen atom and 4 to 15 ring carbon atoms and which is optionally mono- or disubstituted by C1-C4-alkoxy, or the physiologically tolerated salts thereof, which compound is in the form of an agglomerate and is stabilized with a polymeric protective coating wherein the proportion by weight of the polymeric protective coating is 3 to 25% relative to said compound.
(I) in which R is hydrogen, C1-C4-alkyl or phenyl, R represents C1-C4-alkyl or , in which m is 1, 2, 3 or 4, and A and B are identical or different and denote hydrogen or C1-C4-alkyl, R2 is hydrogen, C1-C4-alkyl or benzyl, R3 is hydrogen or C1-C4-alkyl, and R4 and R5 denote, together with the atoms carrying them, a heterocyclic, mono-, bi- or tricyclic hydrogenated or partially hydrogenated ring system which has one nitrogen atom and 4 to 15 ring carbon atoms and which is optionally mono- or disubstituted by C1-C4-alkoxy, or the physiologically tolerated salts thereof, which compound is in the form of an agglomerate and is stabilized with a polymeric protective coating wherein the proportion by weight of the polymeric protective coating is 3 to 25% relative to said compound.
2. Ramipril in the form of an agglomerate stabilized with a polymeric protective coating, wherein the proportion by weight of the polymeric protective coating is 3 to 25%
relative to said ramipril.
relative to said ramipril.
3. A process for the preparation of the composition of claim 1, which comprises coating said compound with an amount of a polymeric protective film sufficient so that the proportion by weight of the polymeric protective coating is 3 to 25% relative to said compound, and compressing said coated compound.
4. The composition of claim 1, further containing a buffer.
5. A process for the manufacture of the composition of claim 1, which comprises coating said compound or a mixture containing said compound with a polymeric protective film, wherein the proportion by weight of the polymeric protective coating is 3 to 25% relative to said compound, and compressing said coated compound or mixture.
6. The process of claim 3, comprising the additional step of adjusting with a buffer the environment of the compound of formula I to a pH range from 5.5 to 8.
7. The process of claim 5, wherein the compound of formula I is ramipril and wherein the proportion by weight of the protective coating is 5 to 15% relative to said compound.
8. A method for the manufacture of a stable pharmaceutical formulation in compressed form, comprising incorporating the coated compound of claim 1 in said pharmaceutical formulation.
9. The composition of claim 1, wherein the proportion by weight of the polymeric protective coating is 5 to 15%
relative to said compound of formula I.
relative to said compound of formula I.
10. The composition of claim 1, wherein the proportion by weight of the polymeric protective coating is 15% relative to said compound of formula I.
11. The process of claim 3, further comprising mixing said compound with a physiologically tolerated buffer.
12. The process of claim 6, wherein said pH range is from 6.5 to 7.
13. The process of claim 5, wherein said compound is mixed with a suitable auxiliary.
14. The process of claim 6, wherein the compound of formula I is ramipril.
15. The process of claim 6, wherein said pH is adjusted by incorporating said buffer into said polymeric protective coating.
16. The process of claim 7, wherein the proportion by weight of the protective coating is 15% relative to said compound.
17. The composition of claim 9, wherein said compound of formula I is ramipril.
18. The composition of claim 10, wherein said compound of formula I is ramipril.
19. Ramipril of claim 2, wherein the proportion by weight of the polymeric protective coating is 5 to 15% relative to said ramipril.
20. Ramipril of claim 19, wherein the proportion by weight of the polymeric protective coating is 15% relative to said ramipril.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19873739690 DE3739690A1 (en) | 1987-11-24 | 1987-11-24 | STABILIZED MEDICINAL PRODUCTS, METHOD FOR THEIR PRODUCTION AND STABLE MEDICAL PREPARATIONS |
| DEP3739690.0 | 1987-11-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1338344C true CA1338344C (en) | 1996-05-21 |
Family
ID=6341084
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000583952A Expired - Lifetime CA1338344C (en) | 1987-11-24 | 1988-11-23 | Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulations |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US5151433A (en) |
| EP (1) | EP0317878B1 (en) |
| JP (1) | JPH0768140B2 (en) |
| KR (1) | KR970004908B1 (en) |
| CN (1) | CN1028962C (en) |
| AT (1) | ATE74513T1 (en) |
| AU (1) | AU615495B2 (en) |
| CA (1) | CA1338344C (en) |
| DE (2) | DE3739690A1 (en) |
| DK (1) | DK168423B1 (en) |
| ES (1) | ES2033400T3 (en) |
| FI (1) | FI93693C (en) |
| GR (1) | GR3004925T3 (en) |
| HU (1) | HU202100B (en) |
| IE (1) | IE61173B1 (en) |
| IL (1) | IL88460A0 (en) |
| NO (1) | NO176550C (en) |
| NZ (1) | NZ227032A (en) |
| PH (1) | PH27416A (en) |
| PT (1) | PT89061B (en) |
| ZA (1) | ZA888734B (en) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI94339C (en) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Process for the preparation of pharmaceutically acceptable [R- (R *, R *)] - 2- (4-fluorophenyl) -, - dihydroxy-5- (1-methylethyl) -3-phenyl-4 - [(phenylamino) carbonyl] -1H- for the preparation of pyrrole-1-heptanoic acid and its pharmaceutically acceptable salts |
| US6300361B1 (en) | 1990-07-25 | 2001-10-09 | Novartis Ag | Stabilized pharmaceutical compositions comprising acid donors |
| TW483763B (en) * | 1994-09-02 | 2002-04-21 | Astra Ab | Pharmaceutical composition comprising of ramipril and dihydropyridine compound |
| KR100459029B1 (en) * | 1995-12-27 | 2006-03-27 | 얀센 파마슈티카 엔.브이. | Bioadhesive Solid Dosing Type |
| SE9903028D0 (en) | 1999-08-27 | 1999-08-27 | Astra Ab | New use |
| HUP0203326A3 (en) * | 1999-08-30 | 2003-04-28 | Sanofi Aventis Deutschland | Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events |
| US20030225124A1 (en) * | 1999-08-31 | 2003-12-04 | Spiridon Spireas | Stable formulations of ACE inhibitors, and methods for preparation thereof |
| FR2824477B1 (en) * | 2001-05-09 | 2005-09-09 | Ethypharm Lab Prod Ethiques | ENVELOPED GRANULES BASED ON INHIBITOR OF THE ANFIOTENSIN CONVERTING ENZYME, PROCESS FOR THEIR PREPARATION AND ORODISPERSIBLE TABLETS CONTAINING COATED GRANULES |
| CA2357982A1 (en) * | 2001-09-28 | 2003-03-28 | Bernard Charles Sherman | Solid compositions comprising ramipril |
| AU2003201071A1 (en) * | 2002-01-15 | 2003-07-30 | Ranbaxy Laboratories Limited | Stable pharmaceutical compositions comprising ace inhibitor(s) |
| GB0301471D0 (en) * | 2003-01-22 | 2003-02-19 | Biochemie Gmbh | Organic compounds |
| US20060177498A1 (en) * | 2003-01-22 | 2006-08-10 | Ramaswami Bharatrajan | Solid pharmaceutical composition comprising ramipril |
| WO2005002548A1 (en) * | 2003-06-26 | 2005-01-13 | Teva Pharmaceutical Industries Ltd. | Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives |
| US6869963B2 (en) * | 2003-07-11 | 2005-03-22 | Sandoz Ag | Stable pharmaceutical compositions containing an ACE inhibitor |
| US20060188568A1 (en) * | 2003-10-30 | 2006-08-24 | Lupin Limited | Stable formulations of ace inhibitors and methods for preparation thereof |
| GB2394660A (en) * | 2003-12-17 | 2004-05-05 | Niche Generics Ltd | Stabilisation of pharmaceutical compositions comprising ACE inhibitor by absence of acidic excipients having large specific surface area, eg silicon dioxide |
| GB2411355B (en) * | 2004-02-27 | 2006-02-22 | Niche Generics Ltd | Pharmaceutical composition |
| US20080234353A1 (en) | 2004-03-24 | 2008-09-25 | Reynir Eyjolfsson | Formulations of Ramipril |
| US20060045911A1 (en) * | 2004-08-27 | 2006-03-02 | Sun Pharmaceutical Industries Ltd. | Stable pharmaceutical formulations |
| CN101098679A (en) * | 2004-11-05 | 2008-01-02 | 国王医药研究与发展有限公司 | Stabilized ramipril compositions and methods of making |
| WO2006048895A1 (en) * | 2004-11-08 | 2006-05-11 | Rubicon Research Pvt. Ltd. | Aqueous pharmaceutical coating |
| GB0518129D0 (en) * | 2005-09-06 | 2005-10-12 | Arrow Int Ltd | Ramipril formulation |
| KR100679166B1 (en) | 2005-10-04 | 2007-02-06 | 신풍제약주식회사 | Stabilized pharmaceutical composition and process for preparation thereof |
| US20070098782A1 (en) * | 2005-10-28 | 2007-05-03 | Selamine Limited | Ramipril Formulation |
| GB2431579A (en) * | 2005-10-28 | 2007-05-02 | Arrow Int Ltd | Ramipril formulations |
| RU2008142623A (en) * | 2006-03-28 | 2010-05-10 | Джелесис, Инк. (Us) | METHOD AND MEDICINAL PRODUCT FOR INCREASING HYDROGEL SWELLABILITY AND / OR DURATION OF ITS ACTIVITY IN THE STOMACH OF ANIMAL ORGANISM, METHOD AND MEDICINAL PRODUCT FOR DELIVERY OF MEDICINE |
| US20070232680A1 (en) * | 2006-04-04 | 2007-10-04 | Vijayabhaskar Bolugoddu | Preparation of ramipril and stable pharmaceutical compositions |
| EP1901739A2 (en) * | 2006-04-19 | 2008-03-26 | Teva Pharmaceutical Industries Ltd | Stable pharmaceutical compositions of 2-aza-bicyclo[3.3.0]-octane-3-carboxylic acid derivatives |
| MX2008015343A (en) * | 2006-06-02 | 2008-12-16 | Teva Pharma | Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof. |
| DE602006000402T8 (en) * | 2006-06-02 | 2009-04-09 | Teva Pharmaceutical Industries Ltd. | Stable preparation containing a moisture-sensitive active substance and process for the preparation of the preparation. |
| US20070281000A1 (en) * | 2006-06-02 | 2007-12-06 | Michael Fox | Stable formulation comprising moisture sensitive drug/s and manufacturing procedure thereof |
| US20100035955A1 (en) * | 2006-06-30 | 2010-02-11 | Panagiotis Keramidas | Stabilised Composition Comprising ACE Inhibitors |
| MX2009002091A (en) * | 2006-08-28 | 2009-03-09 | Sanofi Aventis Deutschland | Methods of lowering glucose levels. |
| GB0624090D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amine salts |
| GB0624084D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril amino acid salts |
| GB0624087D0 (en) * | 2006-12-01 | 2007-01-10 | Selamine Ltd | Ramipril combination salt |
| PL382311A1 (en) * | 2007-04-27 | 2008-11-10 | Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna | Pharmaceutical composition with improved stability containing inhibitor of acethylolinoesterasis or its pharmaceutically admitted salt and its production method |
| MX2010010479A (en) | 2008-03-28 | 2011-02-22 | Ferrer Int | Capsule for the prevention of cardiovascular diseases. |
| WO2010030735A2 (en) * | 2008-09-11 | 2010-03-18 | Aethos Pharmaceuticals, Inc. | Stabilized coating for pharmaceutical formulations |
| TR200906322A2 (en) | 2009-08-17 | 2011-07-21 | Bi̇lgi̇ç Mahmut | Granules with improved solubility and stability properties. |
| ES2364011B1 (en) | 2009-11-20 | 2013-01-24 | Gp Pharm, S.A. | CAPSULES OF PHARMACEUTICAL ACTIVE AND ESTERS OF POLYINSATURATED FATTY ACIDS FOR THE TREATMENT OF CARDIOVASCULAR DISEASES. |
| EA030466B1 (en) | 2012-02-17 | 2018-08-31 | Эгиш Дьёдьсердьяр Зрт. | Pharmaceutical formulation having improved stability |
| PL227900B1 (en) | 2012-11-15 | 2018-01-31 | Adamed Spolka Z Ograniczona Odpowiedzialnoscia | Pharmaceutical composition comprising an ACE inhibitor and a calcium channel blocker, a method for its preparation and the dosage unit comprising the composition |
| HUP1300496A2 (en) | 2013-08-16 | 2015-03-02 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Stable pharmaceutical composition |
| TWI668285B (en) * | 2015-12-31 | 2019-08-11 | 長興材料工業股份有限公司 | Thermally polymerizable composition, combonied solution formed therefrom and use thereof |
| EP3275432A1 (en) | 2016-07-25 | 2018-01-31 | H e x a l Aktiengesellschaft | Dosage form with ace inhibitor |
| WO2021162562A2 (en) | 2020-02-10 | 2021-08-19 | Adamed Pharma S.A. | Stable ramipril composition and fixed dose composition comprising thereof |
| CN115068434B (en) * | 2022-08-03 | 2023-05-09 | 昆山龙灯瑞迪制药有限公司 | Preparation method of ramipril tablet |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3565559A (en) * | 1968-03-11 | 1971-02-23 | Sumitomo Chemical Co | Process for making microcapsules |
| IL58849A (en) * | 1978-12-11 | 1983-03-31 | Merck & Co Inc | Carboxyalkyl dipeptides and derivatives thereof,their preparation and pharmaceutical compositions containing them |
| US4344949A (en) * | 1980-10-03 | 1982-08-17 | Warner-Lambert Company | Substituted acyl derivatives of 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids |
| DE3039073A1 (en) * | 1980-10-16 | 1982-05-19 | Röhm GmbH, 6100 Darmstadt | COATED ACETYL SALICYL ACID PREPARATION |
| DE3174844D1 (en) * | 1980-10-23 | 1986-07-24 | Schering Corp | Carboxyalkyl dipeptides, processes for their production and pharmaceutical compositions containing them |
| US4425355A (en) * | 1981-02-17 | 1984-01-10 | Warner-Lambert Company | Substituted acyl derivatives of chair form of octahydro-1H-indole-2-carboxylic acids |
| DE3226768A1 (en) * | 1981-11-05 | 1983-05-26 | Hoechst Ag, 6230 Frankfurt | DERIVATIVES OF CIS, ENDO-2-AZABICYCLO- (3.3.0) -OCTAN-3-CARBONIC ACID, METHOD FOR THE PRODUCTION THEREOF, THE MEANS CONTAINING THEM AND THE USE THEREOF |
| JPH0759499B2 (en) * | 1984-02-10 | 1995-06-28 | ベンツォン ファーマ エイ／エス | Diffusion coated composite unit dose |
| DE3413710A1 (en) * | 1984-04-12 | 1985-10-24 | Hoechst Ag, 6230 Frankfurt | METHOD FOR TREATING HEART INSUFFICIENCY |
| CA1232488A (en) * | 1984-04-13 | 1988-02-09 | Macewans Machinery Limited | Heating apparatus |
| CA1259924A (en) * | 1985-03-25 | 1989-09-26 | Wallace E. Becker | Pharmaceutical tableting method |
| DE3610391A1 (en) * | 1986-03-27 | 1987-10-08 | Hoechst Ag | COMPOUNDS WITH NOOTROPPER ACTION, THESE CONTAINERS AND THEIR USE IN THE TREATMENT AND PROPHYLAXIS OF COGNITIVE DYSFUNCTIONS |
| GB8616669D0 (en) * | 1986-07-09 | 1986-08-13 | Merk Sharpe & Dohme Ltd | Pharmaceutical compositions |
| US4743450A (en) * | 1987-02-24 | 1988-05-10 | Warner-Lambert Company | Stabilized compositions |
| CA1323833C (en) * | 1987-04-28 | 1993-11-02 | Yatindra M. Joshi | Pharmaceutical compositions in the form of beadlets and method |
| US4808413A (en) * | 1987-04-28 | 1989-02-28 | E. R. Squibb & Sons, Inc. | Pharmaceutical compositions in the form of beadlets and method |
| US4898732A (en) * | 1988-05-04 | 1990-02-06 | The Clinipad Corporation | Inhibiting of tumor growth with an antagonist of the renin-angioten-sin system |
-
1987
- 1987-11-24 DE DE19873739690 patent/DE3739690A1/en not_active Withdrawn
-
1988
- 1988-11-15 EP EP88119014A patent/EP0317878B1/en not_active Expired - Lifetime
- 1988-11-15 AT AT88119014T patent/ATE74513T1/en not_active IP Right Cessation
- 1988-11-15 ES ES198888119014T patent/ES2033400T3/en not_active Expired - Lifetime
- 1988-11-15 DE DE8888119014T patent/DE3869919D1/en not_active Expired - Lifetime
- 1988-11-22 HU HU885992A patent/HU202100B/en unknown
- 1988-11-22 NZ NZ227032A patent/NZ227032A/en unknown
- 1988-11-22 FI FI885398A patent/FI93693C/en not_active IP Right Cessation
- 1988-11-22 JP JP63293761A patent/JPH0768140B2/en not_active Expired - Lifetime
- 1988-11-22 PH PH37849A patent/PH27416A/en unknown
- 1988-11-22 US US07/274,598 patent/US5151433A/en not_active Expired - Lifetime
- 1988-11-22 ZA ZA888734A patent/ZA888734B/en unknown
- 1988-11-23 AU AU25818/88A patent/AU615495B2/en not_active Expired
- 1988-11-23 IE IE350588A patent/IE61173B1/en not_active IP Right Cessation
- 1988-11-23 IL IL88460A patent/IL88460A0/en not_active IP Right Cessation
- 1988-11-23 PT PT89061A patent/PT89061B/en not_active IP Right Cessation
- 1988-11-23 CA CA000583952A patent/CA1338344C/en not_active Expired - Lifetime
- 1988-11-23 DK DK653688A patent/DK168423B1/en not_active IP Right Cessation
- 1988-11-23 CN CN88108057A patent/CN1028962C/en not_active Expired - Lifetime
- 1988-11-23 KR KR1019880015400A patent/KR970004908B1/en not_active IP Right Cessation
- 1988-11-23 NO NO885213A patent/NO176550C/en unknown
-
1992
- 1992-06-17 GR GR920401112T patent/GR3004925T3/el unknown
-
1994
- 1994-02-10 US US08/194,634 patent/US5442008A/en not_active Expired - Lifetime
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1338344C (en) | Stabilized medicinal substances, a process for the preparation thereof, and stable medicinal formulations | |
| US4404183A (en) | Sustained release pharmaceutical composition of solid medical material | |
| IE70907B1 (en) | Pharmaceutical tablet pharmaceutical granulate and process for their preparation | |
| HU217629B (en) | Process for producing stabilized pharmaceutical compositions comprising fluvastatin | |
| JP2004043506A (en) | Production method for solid preparation containing gabapentin | |
| EP0966299B1 (en) | Novel oral formulations of calcitonin | |
| AU742382B2 (en) | Pharmaceutical preparation containing levothyroxine sodium | |
| EP0488139B1 (en) | Pharmaceutical composition comprising calcium polycarbophil | |
| EP1976522B1 (en) | Pharmaceutical composition containing montelukast | |
| US5977127A (en) | Cilansetron pharmaceutical preparation stabilized against racemization | |
| WO2008132756A1 (en) | Stable pharmaceutical compositions of ramipril | |
| EP2101742B1 (en) | Pharmaceutical composition containing clopidogrel hydrogenesulphate of polymorph 1 form | |
| JPH04210638A (en) | Pharmaceutical preparation for oral administration in fluid form | |
| IE65373B1 (en) | A tablet and granulate containing mesna as active substance | |
| EP0319074A1 (en) | Pharmaceutical composition and process for its preparation | |
| AU2003201879B2 (en) | Pharmaceutical composition comprising 2,2-Dichloro-12-(4-chlorophenyl)-dodecanoic acid | |
| KR102533637B1 (en) | Crystal form of compound and fumaric acid, pharmaceutical composition and method for treating coronavirus-induced diseases | |
| KR20190076702A (en) | Pharmaceutical formulation comprising benzimidazole and preparation method thereof | |
| HU215191B (en) | Process for the production of controlled release medical preparations for the treatment of dopamine-deficiency, containing a combination of levodopa and carbidopa as active substances | |
| NZ270729A (en) | Fluvastatin sodium in an alkaline carrier |